<DOC>
	<DOCNO>NCT01136798</DOCNO>
	<brief_summary>The investigator propose pilot study test novel hypothesis Exenatide treatment patient type 2 diabetes result improve sleep duration quality explore relationship improvement sleep measure metabolic circadian function . This project would first probe relationship incretin hormone regulation , duration intensity sleep , glucose tolerance circadian dysfunction diabetic patient .</brief_summary>
	<brief_title>Impact Exenatide Sleep Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients diagnosis T2DM base physician documentation accord establish guideline eligible . Patients unstable cardiac , neurological psychiatric disease Women pregnant report try get pregnant exclude . Patients treat obstructive sleep apnea ( OSA ) exclude . Patients establish OSA include decline treatment OSA . Patients morbid obesity ( BMI â‰¥ 40 gk/m2 ) Patients insulin Patients already take incretinbased drug include Patients renal disease ( creatinine clearance &lt; 30 ml/min ) , gastroparesis history pancreatitis also exclude base know possible adverse medication side effect . Patients take insulin secretagogue exclude . Patients Hemoglobin A1c value great equal 10 exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>slow wave sleep</keyword>
	<keyword>effect exenatide therapy sleep patient type 2 diabetes</keyword>
</DOC>